Sangamo BioSciences | SGMO - Capital Ordinário





Capital Ordinário Alterar Data
Alaunos Therapeutics USD 2.38M 172K 2026-03
Alnylam Pharmaceuticals USD 133.73M 290K 2026-06
Alterity Therapeutics Limited AUD 10.88B 10.66B 2025-12
Amgen USD 541M 1000K 2026-06
Bayer EUR 982.42M 0 2026-06
BioCryst Pharmaceuticals USD 255.26M 42.2M 2026-06
Biogen USD 146.7M 200K 2025-09
BioMarin Pharmaceutical USD 193.54M 267K 2026-06
Cipla INR 807.78M 17K 2026-03
Clal Biotechnology ILS 1.61M 0 2022-12
Compugen USD 94.55M 1000 2026-03
CSL USD 482.13M 93.87M 2025-12
Gilead Sciences USD 1.24B 1000K 2026-06
GlaxoSmithKline GBP 4.08B 20.6M 2026-06
Grifols EUR 680.58M 846.11K 2025-12
Ionis Pharmaceuticals USD 165.64M 265K 2026-06
J&J USD 2.41B 1.35M 2026-03
Karyopharm Therapeutics USD 22.54M 4.23M 2026-03
Merck USD 2.47B 4.93M 2026-03
Novartis USD 1.9B 7.38M 2026-06
Omeros USD 611K 17K 2023-12
Pfizer USD 5.7B 0 2026-06
Roche Holding CHF 796.77M 1.15M 2026-06
Sanofi EUR 1.21B 8.25M 2026-03
Sarepta Therapeutics USD 105.62M 53K 2026-06
Tectonic Therapeutic USD 18.83M 92.19K 2026-03
Ultragenyx Pharmaceutical USD 98.3M 1.7M 2026-03
Vertex Pharmaceuticals USD 253.3M 900K 2026-06